rank,account_name,fit,urgency,total,fit_reason,urgency_reason,urgency_source,trigger_summary,best_fit_trial_title,best_fit_trial_status,best_fit_trial_phase,best_fit_trial_url,best_urgency_trial_title,best_urgency_trial_status,best_urgency_trial_phase,best_urgency_trial_url,sec_matched_total,patent_matched_total,target_roles
1,AstraZeneca,5.0,3.0,22.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_candidate: A Study of AZD0120 in Autoimmune Diseases | trial_candidate: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subje | sec_filing: 6-K filed 2026-02-10 – FINAL RESULTS",Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT04257578,A Study of AZD0120 in Autoimmune Diseases,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07295847,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
2,Pfizer,4.0,3.0,20.1,molecule match: elranatamab,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_candidate: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients  | trial_candidate: A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) | trial_candidate: A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With D",A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30),RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06215118,A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30),RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06215118,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
3,Allogene Therapeutics,5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_candidate: A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in A | trial_candidate: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | trial_candidate: Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma","A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07085104,"A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07085104,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
4,"Kite, A Gilead Company",5.0,3.0,20.1,CAR-T trial,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_candidate: Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | trial_candidate: Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma | trial_collaborator: Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL),Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond,NOT_YET_RECRUITING,,https://clinicaltrials.gov/study/NCT07375628,Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1),ACTIVE_NOT_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05396885,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
5,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_candidate: A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relap | trial_candidate: A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With R | trial_candidate: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With",Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT06297226,"A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06220201,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
6,"Chongqing Precision Biotech Co., Ltd",5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: Study of CD19 CAR-T Therapy for Refractory SLE | trial_collaborator: Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus | trial_candidate: Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE,Study of CD19 CAR-T Therapy for Refractory SLE,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07403097,Study of CD19 CAR-T Therapy for Refractory SLE,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07403097,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
7,Nanjing Legend Biotech Co.,5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopath | trial_candidate: A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases | trial_candidate: A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases,A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06869278,A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM),RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07331272,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
8,"Hebei Senlang Biotechnology Inc., Ltd.",5.0,3.0,20.1,CAR-T trial,NOT_YET_RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_collaborator: SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | trial_candidate: Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. | trial_candidate: Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL,SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma,NOT_YET_RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT07234721,Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.,NOT_YET_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07244380,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
9,Miltenyi Biomedicine GmbH,5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblas | trial_candidate: DALY II Japan/MB-CART2019.1 for DLBCL | trial_candidate: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients,CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07361029,CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07361029,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
10,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_candidate: Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies | trial_candidate: Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymph | trial_candidate: PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma,Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases,NOT_YET_RECRUITING,NA,https://clinicaltrials.gov/study/NCT06871644,PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07188610,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
11,Bioray Laboratories,5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: Universal CAR-T Cell Therapy for MM | trial_candidate: The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma | trial_candidate: Universal CAR-T Cell Therapy for NHL,Universal CAR-T Cell Therapy for MM,RECRUITING,NA,https://clinicaltrials.gov/study/NCT07248176,The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05741359,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
12,Bristol-Myers Squibb,5.0,3.0,20.1,CAR-T trial,"NOT_YET_RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_collaborator: CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis | trial_collaborator: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients  | trial_collaborator: Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel,"Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies",ACTIVE_NOT_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT04205409,CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis,NOT_YET_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT07388277,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
13,"Guangzhou Bio-gene Technology Co., Ltd",5.0,3.0,20.1,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_collaborator: Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML | trial_candidate: BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma | trial_candidate: BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors,Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML,NOT_YET_RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT07338357,Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06118788,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
14,"Nanjing IASO Biotechnology Co., Ltd.",5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies | trial_candidate: UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies | trial_candidate: A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03),Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis,NOT_YET_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07055724,IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07309900,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
15,Novartis,5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL | trial_collaborator: Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma | trial_collaborator: French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T),Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07250087,Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07250087,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
16,Bellicum Pharmaceuticals,5.0,3.0,20.1,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_collaborator: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | trial_collaborator: Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | trial_collaborator: Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refract,Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer,RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT05620342,Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06096038,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
17,"Beijing Immunochina Medical Science & Technology Co., Ltd.",5.0,3.0,20.1,CAR-T trial,NOT_YET_RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric  | trial_candidate: Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Ery | trial_candidate: Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus,Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction,NOT_YET_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07406984,Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction,NOT_YET_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07406984,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
18,"Nanjing Bioheng Biotech Co., Ltd.",5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases | trial_collaborator: CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases | trial_candidate: A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.,Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases,RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT06775912,CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06622694,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
19,Novartis Pharmaceuticals,5.0,3.0,20.1,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,"trial_candidate: Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis | trial_candidate: Phase 2 Study of Rapcabtagene Autoleucel in Myositis | trial_collaborator: A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lympho",CAR-T Long Term Follow Up (LTFU) Study,RECRUITING,PHASE3,https://clinicaltrials.gov/study/NCT02445222,"Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis",RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06704269,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
20,Genmab,5.0,3.0,20.1,CAR-T trial,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_candidate: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | trial_candidate: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and | trial_candidate: GEN1047 for Solid Tumors - First in Human (FIH) Trial,Epcoritamab-CAR T Cells for Large B-cell Lymphomas,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT06458439,Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05660967,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
21,Kyverna Therapeutics,5.0,3.0,20.1,CAR-T trial,"RECRUITING in high urgency phase (PHASE2,PHASE3)",clinicaltrials,"trial_candidate: A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 | trial_candidate: KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia | trial_collaborator: A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple ","KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis",RECRUITING,"PHASE2,PHASE3",https://clinicaltrials.gov/study/NCT06193889,"KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis",RECRUITING,"PHASE2,PHASE3",https://clinicaltrials.gov/study/NCT06193889,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
22,Juventas Cell Therapy Ltd.,5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases | trial_collaborator: Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma | trial_candidate: A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases,Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06676982,Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06676982,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
23,Fate Therapeutics,5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_candidate: A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | trial_candidate: FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | trial_candidate: FT819 in Subjects With B-cell Malignancies","FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06241456,A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06308978,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
24,Carbiogene Therapeutics Co. Ltd.,5.0,3.0,20.1,CAR-T trial,NOT_YET_RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Panc | trial_candidate: Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma | trial_collaborator: Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma,Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer,NOT_YET_RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT07394205,Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma,NOT_YET_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06705725,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
25,AbbVie,5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_collaborator: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed | trial_candidate: A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | trial_collaborator: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma",MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT06414148,"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT04872790,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
26,Autolus Limited,5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE2),clinicaltrials,"trial_collaborator: A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | trial_candidate: Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus | trial_candidate: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphob",A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL),ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT04404660,A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07400029,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
27,iCell Gene Therapeutics,5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: CD4CAR for CD4+ Leukemia and Lymphoma | trial_collaborator: Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myel | trial_collaborator: Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia ,"Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06071624,CD4CAR for CD4+ Leukemia and Lymphoma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT03829540,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
28,"CARsgen Therapeutics Co., Ltd.",5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_collaborator: Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC | trial_collaborator: A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell  | trial_collaborator: Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE","A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus",RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT07339332,"Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07031713,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
29,"Rui Therapeutics Co., Ltd",5.0,3.0,20.1,CAR-T trial,NOT_YET_RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of R | trial_collaborator: Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatm | trial_collaborator: RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies,An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease,RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT07241468,RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies,NOT_YET_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07105735,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
30,Yake Biotechnology Ltd.,5.0,3.0,20.1,CAR-T trial,"NOT_YET_RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_collaborator: Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia | trial_collaborator: A Multicenter Study of CAR-T Cells in Primary Ph+All | trial_collaborator: Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia,Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia,NOT_YET_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT07370064,Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia,NOT_YET_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT07370064,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
31,"Shanghai Xiniao Biotech Co., Ltd.",5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases | trial_collaborator: Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD1 | trial_collaborator: CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases,CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07315087,CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07315087,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
32,"Hebei Taihe Chunyu Biotechnology Co., Ltd",5.0,3.0,20.1,CAR-T trial,"NOT_YET_RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,"trial_collaborator: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human  | trial_collaborator: CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma | trial_collaborator: Autologous Transplantation Combined With BCMA CAR-T in the Treatment of Young NDMM","Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma",NOT_YET_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT07259070,"Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma",NOT_YET_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT07259070,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
33,"Genentech, Inc.",5.0,3.0,20.1,CAR-T trial,NOT_YET_RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_candidate: A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20- | trial_collaborator: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lym | trial_collaborator: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MC",Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05633615,"A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)",NOT_YET_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06984341,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
34,"Gracell Biotechnologies (Shanghai) Co., Ltd.",5.0,3.0,20.1,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_candidate: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma | trial_collaborator: GC012F Injection in Refractory Idiopathic Inflammatory Myopathy | trial_candidate: A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus,"Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07250269,A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06235229,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
35,A2 Biotherapeutics Inc.,5.0,3.0,20.1,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,"trial_candidate: A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With So | trial_candidate: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | trial_candidate: A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With S","A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06051695,"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06051695,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
36,"Poseida Therapeutics, Inc.",5.0,3.0,20.1,CAR-T trial,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | trial_candidate: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma | trial_candidate: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies,P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05239143,P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05239143,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
37,Cabaletta Bio,5.0,3.0,20.1,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,"trial_candidate: RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia  | trial_candidate: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody  | trial_candidate: RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Activ","A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)",RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT04422912,RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06359041,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
38,Takeda,5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_collaborator: A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | trial_candidate: A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myel | trial_collaborator: IVIG for Infection Prevention After CAR-T-Cell Therapy",IVIG for Infection Prevention After CAR-T-Cell Therapy,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05952804,A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05748197,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
39,Cartesian Therapeutics,5.0,3.0,20.1,CAR-T trial,NOT_YET_RECRUITING in high urgency phase (PHASE2),clinicaltrials,"trial_candidate: Descartes-08 in Autoantibody Myositis | trial_candidate: Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia G | trial_candidate: Descartes-08 for Patients With Systemic Lupus Erythematosus","Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis",RECRUITING,PHASE3,https://clinicaltrials.gov/study/NCT06799247,Descartes-08 in Autoantibody Myositis,NOT_YET_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07391605,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
40,Merck Sharp & Dohme LLC,5.0,3.0,20.1,CAR-T trial,RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_candidate: A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive an | trial_candidate: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or  | trial_collaborator: Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukem,Pembro Plus CAR T-cell Therapy in R/R in PMBCL,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05934448,A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006),RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05458297,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
